Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will release earnings results for its fourth quarter, before the opening bell on Tuesday, March 24.
Analysts expect the Research Triangle Park, North Carolina-based company to report quarterly earnings at 4 cents per share, versus a year-ago loss of 6 cents per share. The consensus estimate for Core & Main’s quarterly revenue is $14.73 million, versus $7.92 million a year earlier, according to data from Benzinga Pro.
On March 16, Fennec Pharmaceuticals announced a settlement agreement resolving PEDMARK patent litigation.
Fennec Pharmaceuticals shares gained 1.8% to close at $7.45 on Monday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company …